{
    "clinical_study": {
        "@rank": "139708", 
        "acronym": "BPH", 
        "arm_group": {
            "arm_group_label": "Silodosin", 
            "arm_group_type": "Experimental", 
            "description": "Silodosin, 8 mg, once daily, orally administered with dinner for 12 weeks"
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to determine safety and efficacy of silodosin, which is a\n      treatment for benign prostatic hyperplasia with high selectivity to \u03b11A-receptor, on\n      patients with benign prostatic hyperplasia accompanied by nocturia."
        }, 
        "brief_title": "Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia", 
        "condition": [
            "Nocturia", 
            "Benign Prostatic Hyperplasia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Prostatic Hyperplasia", 
                "Hyperplasia", 
                "Nocturia"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is designed as a multi-center, prospective, open-label and single-arm study.\n      Subjects who are willing to provide written informed consent will be enrolled after\n      screening for eligibility criteria. The subjects will be administered with investigational\n      product for 12 weeks and visit as outpatients for evaluation of safety and efficacy at\n      baseline (visit 2) and 4 weeks (visit 3) and 12 weeks (visit 4) after baseline."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males of at least 50 years of age, with current diagnosis of benign prostatic\n             hyperplasia\n\n          -  Symptoms of nocturia evidenced by \u22652 episodes per night in average according to 3-day\n             voiding diary\n\n          -  More than total of 8 points on IPSS and 3 points on QoL\n\n          -  Able to provide written informed consent and to comply with all study procedures\n\n        Exclusion Criteria:\n\n          -  PSA level > 10 ng/\u3396 (except patients who had 4 ng/\u3396 < PSA level \u2264 10 ng/\u3396 6 months\n             prior to screening and identified as negative from biopsy)\n\n          -  Symptoms of postural hypotension\n\n          -  Severe renal disorders or creatinine clearance \u2265 2.0 mg/dL\n\n          -  Severe hepatic disorders or AST or ALT \u2265 3 x upper limit of normal (ULN)\n\n          -  Severe cardiac disorders or development or diagnosis of vascular disorder (unstable\n             angina, myocardial infarction, cerebral infarction, cerebral hemorrhage, coronary\n             artery bypass graft, etc) 6 months prior to enrollment\n\n          -  Any disorder of the gastrointestinal system which could result in altered digestion\n             or absorption, history of gastrointestinal tract surgery except ecphyadectomy\n\n          -  Patients with bladder cancer, cystolith or urethral stricture\n\n          -  Patients with neurogenic bladder\n\n          -  History of acute urinary retention\n\n          -  Indwelling catheter or self intermittent catheterization\n\n          -  Patients with pyuria 1 month prior to screening\n\n          -  History of prostatic cancer\n\n          -  History of prostatic surgery\n\n          -  Patients with uncontrolled chronic disease\n\n          -  Alcoholism or sustained drug dependent abuse 1 year prior to screening\n\n          -  Hypersensitivity to \u03b11A-receptor blockers\n\n          -  Administration of following drugs within according periods prior to screening - 2\n             weeks: Antimuscarinic agents (Tolterodine, Trospium, Solifenacin, Fesoterodine,\n             Propiverine, Oxybutynin, Flavoxate, etc), Anticholinesterase agents (Neostigmine\n             methylsulfate, etc), Cholinergic agonists (Bethanechol Cl, etc), Benign prostatic\n             hyperplasia agents (Tamsulosin HCl, Prazosin HCl, Terazosin HCl, Doxazosin mesylate,\n             Silodosin, Naftopidil, etc), Tricyclic antidepressants (Amitriptyline, Clomipramine,\n             Dosulepin, Doxepin, Imipramine, Quinupramine, etc), 6 months: 5-\u03b1-Reductase\n             Inhibitors (Finasteride, Dutasteride)\n\n          -  Presence of a condition or abnormality that in the opinion of the investigator would\n             compromise the safety of the patient or the quality of the data"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "126", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 31, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02106182", 
            "org_study_id": "JW-SDS-406"
        }, 
        "intervention": [
            {
                "arm_group_label": "Silodosin", 
                "intervention_name": "Silodosin", 
                "intervention_type": "Drug", 
                "other_name": "Thrupas Cap"
            }, 
            {
                "arm_group_label": "Silodosin", 
                "description": "Subject's overall health state will be evaluated by clinical laboratory tests.\nSerum chemistry test: Creatinine, Blood Urea Nitrogen(BUN), Aspartate aminotransferase(AST), Alanine aminotransferase(ALT) Urinalysis: Urine Specific Gravity, Urine pH, Urine Protein, Urine Glucose, Urine Ketone, Urine Bilirubin, Urine Urobilinogen, Urine Nitrite, Urine Occult Blood(OB), Urine Red Blood Cell(RBC), Urine White Blood Cell(WBC) Immunoassay: Prostate Specific Antigen(PSA)", 
                "intervention_name": "Laboratory tests", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Silodosin", 
                "description": "3-day voiding diaries will be distributed on Visits 1, 2 and 3. Subjects will record incidence of nocturia during 3 days on the diaries within 7 days of Visits 2 (baseline), 3 and 4. The average will be used to confirm the change in incidence of nocturia (at baseline, results from within 1 week from screening may be used but will be excluded for subjects needing wash-out period).", 
                "intervention_name": "3-days voiding diary", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Silodosin", 
                "intervention_name": "12 weeks", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Benign prostatic hyperplasia", 
            "Nocturia", 
            "Silodosin", 
            "Thrupas"
        ], 
        "lastchanged_date": "April 7, 2014", 
        "location": [
            {
                "contact": {
                    "email": "kjc@catholic.ac.kr", 
                    "last_name": "Juncheol Kim, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Bucheon", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do", 
                        "zip": "420-818"
                    }, 
                    "name": "Bucheon St.Mary's Hospital"
                }, 
                "investigator": {
                    "last_name": "Juncheol Kim, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "urochoi@ajou.ac.kr", 
                    "last_name": "Jongbo Choi, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Suwon", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do", 
                        "zip": "443-380"
                    }, 
                    "name": "Ajou University Hospital"
                }, 
                "investigator": {
                    "last_name": "Jongbo Choi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "toohotman@daum.net", 
                    "last_name": "Jeongju Lee, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of", 
                        "zip": "602-739"
                    }, 
                    "name": "Pusan Natonal University Hospital"
                }, 
                "investigator": {
                    "last_name": "Jeongju Lee, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Daegyung Kim, MD", 
                    "phone": "dkkim@eulji.ac.kr"
                }, 
                "facility": {
                    "address": {
                        "city": "Daejeon", 
                        "country": "Korea, Republic of", 
                        "zip": "302-799"
                    }, 
                    "name": "Eulji University Hospital"
                }, 
                "investigator": {
                    "last_name": "Daegyung Kim, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "yssong@schmc.ac.kr", 
                    "last_name": "Yunseop Song, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "140-887"
                    }, 
                    "name": "Soon Chun Hyang University Hospital"
                }, 
                "investigator": {
                    "last_name": "Yunseop Song, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ytkimuro@hanyang.ac.kr", 
                    "last_name": "Yongtae Kim, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "133-792"
                    }, 
                    "name": "Hanyang University Hospital"
                }, 
                "investigator": {
                    "last_name": "Yongtae Kim, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-center, Prospective, Open-label, Single-arm, 12-weeks, Phase IV Trial to Evaluate the Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Descriptive statistics for incidence of nocturia will be provided for each visit. Paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment.", 
            "measure": "Incidence of nocturia", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02106182"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Descriptive statistics for secondary efficacy outcome measures will be provided for each visit. Assessment will be performed on whether the change from baseline to after 12 weeks of treatment has difference. For successive data, paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment.", 
                "measure": "Mean change in International Prostate Symptom Score(IPSS) from baseline", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Descriptive statistics for secondary efficacy outcome measures will be provided for each visit. Assessment will be performed on whether the change from baseline to after 12 weeks of treatment has difference. For successive data, paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment.", 
                "measure": "Mean change in Quality of Life(QoL) scores from baseline", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Descriptive statistics for secondary efficacy outcome measures will be provided for each visit. Assessment will be performed on whether the change from baseline to after 12 weeks of treatment has difference. For successive data, paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment.", 
                "measure": "Mean change in Overactive Bladder Symptom Score(OABSS) from baseline", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Descriptive statistics for secondary efficacy outcome measures will be provided for each visit. Assessment will be performed on whether the change from baseline to after 12 weeks of treatment has difference. For successive data, paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment.", 
                "measure": "Mean change in International Consultation on Incontinence modular Questionnaire-Nocturia(ICIQ-N) from baseline", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Descriptive statistics for secondary efficacy outcome measures will be provided for each visit. Assessment will be performed on whether the change from baseline to after 12 weeks of treatment has difference. For successive data, paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment.", 
                "measure": "Mean change in Questions 3, 5 and 6 (voiding symptoms) of IPSS from baseline", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Descriptive statistics for secondary efficacy outcome measures will be provided for each visit. Assessment will be performed on whether the change from baseline to after 12 weeks of treatment has difference. For successive data, paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment.", 
                "measure": "Mean change in Question 1 (postvoiding symptoms) of IPSS from baseline", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Descriptive statistics for secondary efficacy outcome measures will be provided for each visit. Assessment will be performed on whether the change from baseline to after 12 weeks of treatment has difference. For successive data, paired t-test or Wilcoxon's signed rank test will be used for assessment of change from baseline to after 12 weeks of treatment.", 
                "measure": "Mean change in Questions 2, 4 and 7 (storage symptoms) from baseline", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Ratio of subjects with \u2265 25% decrease in incidence of nocturia", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Ratio of subjects with \u2265 25% decrease in IPSS", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "JW Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "JW Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}